The prototypical ranitidine analog JWS-USC-75-IX improves information processing and cognitive function in animal models

Alvin V Terry, Jerry J. Buccafusco, Elizabeth J. Herman, Patrick Michael Callahan, Wayne D. Beck, Samantha Warner, Leah Vandenhuerk, Kristy Bouchard, Gary M. Schwarz, Jie Gao, James M. Chapman

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

This study was designed to evaluate further a prototypical ranitidine analog, JWS-USC-75-IX, [(3-[[[2-[[(5-dimethylaminomethyl)-2-furanyl]methyl]thio] ethyl]amino]-4-nitropyridazine, JWS], for neuropharmacologic properties that would theoretically be useful for treating cognitive and noncognitive behavioral symptoms of neuropsychiatric disorders. JWS was previously found to inhibit acetylcholinesterase (AChE) activity, serve as a potent ligand at muscarinic M2 acetylcholine receptors, and elicit positive effects on spatial learning, passive avoidance, and working memory in rodents. In the current study, JWS was evaluated for binding activity at more than 60 neurotransmitter receptors, transporters, and ion channels, as well as for inhibitory activity at AChE and butyrylcholinesterase (BChE). The results indicate that JWS inhibits AChE and BChE at low (micromolar) concentrations and that it is a functional antagonist at M2 receptors (KB = 320 nM). JWS was subsequently evaluated orally across additional behavioral assays in rodents (dose range, 0.03-10.0 mg/kg) as well as nonhuman primates (dose range, 0.05-2.0 mg/kg). In rats, JWS improved prepulse inhibition (PPI) of the acoustic startle response in nonimpaired rats and attenuated PPI deficits in three pharmacologic impairment models. JWS also attenuated scopolamine and (-)-5-methyl-10,11- dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate (MK-801)-related impairments in a spontaneous novel object recognition task and a five-choice serial reaction time task, respectively. In monkeys, JWS elicited dose-dependent improvements of a delayed match-to-sample task as well as an attention-related version of the task where randomly presented (task-relevant) distractors were presented. Thus, JWS (potentially via effects at several drug targets) improves information processing, attention, and memory in animal models and could potentially treat the cognitive and behavioral symptoms of some neuropsychiatric illnesses.

Original languageEnglish (US)
Pages (from-to)751-766
Number of pages16
JournalJournal of Pharmacology and Experimental Therapeutics
Volume336
Issue number3
DOIs
StatePublished - Mar 1 2011

Fingerprint

Ranitidine
Acetylcholinesterase
Automatic Data Processing
Cognition
Butyrylcholinesterase
Behavioral Symptoms
Animal Models
Rodentia
Startle Reflex
Neurotransmitter Transport Proteins
Muscarinic M2 Receptors
Neurobehavioral Manifestations
Neurotransmitter Receptor
Imines
Scopolamine Hydrobromide
Dizocilpine Maleate
Muscarinic Receptors
Ion Channels
Short-Term Memory
Acoustics

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

The prototypical ranitidine analog JWS-USC-75-IX improves information processing and cognitive function in animal models. / Terry, Alvin V; Buccafusco, Jerry J.; Herman, Elizabeth J.; Callahan, Patrick Michael; Beck, Wayne D.; Warner, Samantha; Vandenhuerk, Leah; Bouchard, Kristy; Schwarz, Gary M.; Gao, Jie; Chapman, James M.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 336, No. 3, 01.03.2011, p. 751-766.

Research output: Contribution to journalArticle

Terry, Alvin V ; Buccafusco, Jerry J. ; Herman, Elizabeth J. ; Callahan, Patrick Michael ; Beck, Wayne D. ; Warner, Samantha ; Vandenhuerk, Leah ; Bouchard, Kristy ; Schwarz, Gary M. ; Gao, Jie ; Chapman, James M. / The prototypical ranitidine analog JWS-USC-75-IX improves information processing and cognitive function in animal models. In: Journal of Pharmacology and Experimental Therapeutics. 2011 ; Vol. 336, No. 3. pp. 751-766.
@article{00366796fbdb4e5993d0cffb532d1933,
title = "The prototypical ranitidine analog JWS-USC-75-IX improves information processing and cognitive function in animal models",
abstract = "This study was designed to evaluate further a prototypical ranitidine analog, JWS-USC-75-IX, [(3-[[[2-[[(5-dimethylaminomethyl)-2-furanyl]methyl]thio] ethyl]amino]-4-nitropyridazine, JWS], for neuropharmacologic properties that would theoretically be useful for treating cognitive and noncognitive behavioral symptoms of neuropsychiatric disorders. JWS was previously found to inhibit acetylcholinesterase (AChE) activity, serve as a potent ligand at muscarinic M2 acetylcholine receptors, and elicit positive effects on spatial learning, passive avoidance, and working memory in rodents. In the current study, JWS was evaluated for binding activity at more than 60 neurotransmitter receptors, transporters, and ion channels, as well as for inhibitory activity at AChE and butyrylcholinesterase (BChE). The results indicate that JWS inhibits AChE and BChE at low (micromolar) concentrations and that it is a functional antagonist at M2 receptors (KB = 320 nM). JWS was subsequently evaluated orally across additional behavioral assays in rodents (dose range, 0.03-10.0 mg/kg) as well as nonhuman primates (dose range, 0.05-2.0 mg/kg). In rats, JWS improved prepulse inhibition (PPI) of the acoustic startle response in nonimpaired rats and attenuated PPI deficits in three pharmacologic impairment models. JWS also attenuated scopolamine and (-)-5-methyl-10,11- dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate (MK-801)-related impairments in a spontaneous novel object recognition task and a five-choice serial reaction time task, respectively. In monkeys, JWS elicited dose-dependent improvements of a delayed match-to-sample task as well as an attention-related version of the task where randomly presented (task-relevant) distractors were presented. Thus, JWS (potentially via effects at several drug targets) improves information processing, attention, and memory in animal models and could potentially treat the cognitive and behavioral symptoms of some neuropsychiatric illnesses.",
author = "Terry, {Alvin V} and Buccafusco, {Jerry J.} and Herman, {Elizabeth J.} and Callahan, {Patrick Michael} and Beck, {Wayne D.} and Samantha Warner and Leah Vandenhuerk and Kristy Bouchard and Schwarz, {Gary M.} and Jie Gao and Chapman, {James M.}",
year = "2011",
month = "3",
day = "1",
doi = "10.1124/jpet.110.175422",
language = "English (US)",
volume = "336",
pages = "751--766",
journal = "The Journal of pharmacology and experimental therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - The prototypical ranitidine analog JWS-USC-75-IX improves information processing and cognitive function in animal models

AU - Terry, Alvin V

AU - Buccafusco, Jerry J.

AU - Herman, Elizabeth J.

AU - Callahan, Patrick Michael

AU - Beck, Wayne D.

AU - Warner, Samantha

AU - Vandenhuerk, Leah

AU - Bouchard, Kristy

AU - Schwarz, Gary M.

AU - Gao, Jie

AU - Chapman, James M.

PY - 2011/3/1

Y1 - 2011/3/1

N2 - This study was designed to evaluate further a prototypical ranitidine analog, JWS-USC-75-IX, [(3-[[[2-[[(5-dimethylaminomethyl)-2-furanyl]methyl]thio] ethyl]amino]-4-nitropyridazine, JWS], for neuropharmacologic properties that would theoretically be useful for treating cognitive and noncognitive behavioral symptoms of neuropsychiatric disorders. JWS was previously found to inhibit acetylcholinesterase (AChE) activity, serve as a potent ligand at muscarinic M2 acetylcholine receptors, and elicit positive effects on spatial learning, passive avoidance, and working memory in rodents. In the current study, JWS was evaluated for binding activity at more than 60 neurotransmitter receptors, transporters, and ion channels, as well as for inhibitory activity at AChE and butyrylcholinesterase (BChE). The results indicate that JWS inhibits AChE and BChE at low (micromolar) concentrations and that it is a functional antagonist at M2 receptors (KB = 320 nM). JWS was subsequently evaluated orally across additional behavioral assays in rodents (dose range, 0.03-10.0 mg/kg) as well as nonhuman primates (dose range, 0.05-2.0 mg/kg). In rats, JWS improved prepulse inhibition (PPI) of the acoustic startle response in nonimpaired rats and attenuated PPI deficits in three pharmacologic impairment models. JWS also attenuated scopolamine and (-)-5-methyl-10,11- dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate (MK-801)-related impairments in a spontaneous novel object recognition task and a five-choice serial reaction time task, respectively. In monkeys, JWS elicited dose-dependent improvements of a delayed match-to-sample task as well as an attention-related version of the task where randomly presented (task-relevant) distractors were presented. Thus, JWS (potentially via effects at several drug targets) improves information processing, attention, and memory in animal models and could potentially treat the cognitive and behavioral symptoms of some neuropsychiatric illnesses.

AB - This study was designed to evaluate further a prototypical ranitidine analog, JWS-USC-75-IX, [(3-[[[2-[[(5-dimethylaminomethyl)-2-furanyl]methyl]thio] ethyl]amino]-4-nitropyridazine, JWS], for neuropharmacologic properties that would theoretically be useful for treating cognitive and noncognitive behavioral symptoms of neuropsychiatric disorders. JWS was previously found to inhibit acetylcholinesterase (AChE) activity, serve as a potent ligand at muscarinic M2 acetylcholine receptors, and elicit positive effects on spatial learning, passive avoidance, and working memory in rodents. In the current study, JWS was evaluated for binding activity at more than 60 neurotransmitter receptors, transporters, and ion channels, as well as for inhibitory activity at AChE and butyrylcholinesterase (BChE). The results indicate that JWS inhibits AChE and BChE at low (micromolar) concentrations and that it is a functional antagonist at M2 receptors (KB = 320 nM). JWS was subsequently evaluated orally across additional behavioral assays in rodents (dose range, 0.03-10.0 mg/kg) as well as nonhuman primates (dose range, 0.05-2.0 mg/kg). In rats, JWS improved prepulse inhibition (PPI) of the acoustic startle response in nonimpaired rats and attenuated PPI deficits in three pharmacologic impairment models. JWS also attenuated scopolamine and (-)-5-methyl-10,11- dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate (MK-801)-related impairments in a spontaneous novel object recognition task and a five-choice serial reaction time task, respectively. In monkeys, JWS elicited dose-dependent improvements of a delayed match-to-sample task as well as an attention-related version of the task where randomly presented (task-relevant) distractors were presented. Thus, JWS (potentially via effects at several drug targets) improves information processing, attention, and memory in animal models and could potentially treat the cognitive and behavioral symptoms of some neuropsychiatric illnesses.

UR - http://www.scopus.com/inward/record.url?scp=79951976804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951976804&partnerID=8YFLogxK

U2 - 10.1124/jpet.110.175422

DO - 10.1124/jpet.110.175422

M3 - Article

C2 - 21106907

AN - SCOPUS:79951976804

VL - 336

SP - 751

EP - 766

JO - The Journal of pharmacology and experimental therapeutics

JF - The Journal of pharmacology and experimental therapeutics

SN - 0022-3565

IS - 3

ER -